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We investigated the role of interleukin (IL)-4 receptor (IL-4R) 
signalling during mouse carcinogen-induced colorectal carcino-
genesis and in a case–control genetic epidemiological study of 
IL-4Rα single nucleotide polymorphisms (SNPs). Azoxymethane-
induced aberrant crypt focus (ACF; 6 weeks) and tumours (32 
weeks) were analysed in wild-type (WT) BALB/c mice, as well 
as in IL-4Rα−/−, IL-13−/− and ‘double-knockout’ (DKO) animals. 
Colorectal cancer (CRC) cases (1502) and controls (584) were 
genotyped for six coding IL-4Rα SNPs. The association with CRC 
risk and CRC-specific mortality was analysed by logistic regres-
sion. Lack of IL-4Rα expression was associated with increased 
ACFs [median 8.5 ACFs per mouse (IL-4Rα−/−) versus 3 (WT); 
P = 0.007], but no difference in the number of colorectal tumours 
[mean 1.4 per mouse (IL-4Rα−/−) versus 2 (WT)], which were 
smaller and demonstrated reduced nuclear/cytoplasmic β-catenin 
translocation compared with WT tumours. Tumour-bearing 
IL-4Rα−/− mice had fewer CD11b+/Gr1+ myeloid-derived sup-
pressor splenocytes than WT animals. IL-13−/− mice developed a 
similar number of ACFs to IL-4Rα−/− and DKO mice. There was 
a significant increase in CRC risk associated with the functional 
SNP Q576R [odds ratio 1.54 (95% confidence interval 0.94–2.54), 
Ptrend 0.03 for the minor G allele]. There was no effect of IL-4Rα 
genotype on either CRC-specific or all-cause mortality. These 
combined pre-clinical and human data together demonstrate that 
reduced IL-4R signalling has stage-specific effects on colorectal 
carcinogenesis (increased CRC initiation and risk but reduced 
tumour progression and no effect on CRC mortality). These 
results should prompt evaluation of the effect of pharmacologi-
cal manipulation of IL-4R signalling on future CRC risk and for 
CRC treatment.
Introduction
The relatively long natural history of colorectal carcinogenesis in 
humans, which, in the majority of cases, occurs via the benign colo-
rectal adenoma (or polyp) followed by progression through to inva-
sive colorectal adenocarcinoma (or cancer), makes colorectal cancer 
(CRC) particularly amenable to prevention strategies (1). Despite 
significant advances in CRC prevention measures, particularly popu-
lation screening and surveillance based on early detection of CRC 
and polyp removal (2,3), there is still a need for alternative CRC 
prevention strategies such as chemoprevention that could be used to 
minimize the need for invasive endoscopic investigations and the inci-
dence of interval neoplasia (4).
The relationship between chronic inflammation and different stages 
of both colitis-associated and ‘sporadic’ colorectal carcinogenesis, 
from initiation of epithelial cell dysplasia through to promotion of 
metastasis, is firmly established (5). In a small number of instances, 
the role of individual pro-inflammatory genes and mediators linking 
inflammation and intestinal tumorigenesis has been delineated (5). For 
example, the pro-inflammatory transcription factor nuclear factor κB 
has been demonstrated to drive murine intestinal tumour initiation and 
growth, but by different mechanisms involving nuclear factor κB acti-
vation in epithelial cells and in stromal inflammatory cells, respectively 
(6). This nuclear factor κB paradigm highlights that an individual pro-
inflammatory signalling pathway may have different roles during ini-
tiation, promotion or progression of colorectal carcinogenesis.
There is some experimental evidence that signalling by the T helper 
2 cytokines interleukin (IL)-4 and IL-13 also has differential effects 
depending on the stage of colorectal carcinogenesis that is considered. 
IL-4 and IL-13 signal via two distinct receptor heterodimers, both of 
which contain an IL-4 receptor (IL-4R) α chain as a common subunit 
together with either a cytokine receptor common γ chain (termed the 
type I IL-4R) or complexed with a IL-13Rα1 chain (termed the type II 
IL-4R) (7). The type I  IL-4R binds IL-4 exclusively and is expressed 
predominantly by haematopoietic cells. The type II IL-4R can bind both 
IL-4 and IL-13 and is found mainly in non-haematopoietic cells such as 
epithelial cells (8). Signal transduction downstream of both type I and 
type II IL-4Rs occurs via a signal transducer and activator of transcrip-
tion-6 (STAT-6) pathway, which is initiated by receptor dimerization-
induced phosphorylation of the IL-4Rα chain by Janus kinase (8). IL-13 
can also bind a separate receptor IL-13Rα2, expression of which is 
induced by type II IL-4R activation. IL-13Rα2 was previously believed 
to be a decoy receptor, but IL-13–IL-13Rα2 binding has also been impli-
cated in intestinal fibrogenesis via transforming growth factor β (9).
IL-4Rα chain expression has been demonstrated to be increased 
in many human cancers including CRC (10,11) and IL-4R signalling 
has been implicated in driving tumour growth and metastasis in rodent 
models of advanced CRC (8,12–14). Consistent with these data, 
tumour cell-derived IL-4 has been demonstrated to induce antiapop-
totic protein expression in primary human CRC cells (15). IL-4Rα-
mediated signalling also plays a role in the host antitumour immune 
response mediating immunosuppressive activity of tumour-induced 
myeloid-derived suppressor cells (MDSCs) (16).
The role of IL-4R signalling at early stages of colorectal 
carcinogenesis, which are more relevant to CRC prevention, 
has received less attention than activity in CRC models. In the 
azoxymethane (AOM) mouse model of ‘sporadic’ CRC initiation, 
we have previously demonstrated that lack of the IL-4Rα gene was 
associated with an increased number of aberrant crypt focus (ACF), 
an established biomarker of CRC in rodent chemical carcinogenesis 
models (17). In contrast with the conclusions from the rodent CRC 
models, these data suggested a protective, antineoplastic role of 
IL-4Rα-dependent signalling during AOM-induced initiation of 
colorectal carcinogenesis in BALB/c mice, but stopped short of 
determining the individual roles of the T helper 2 cytokines and the 
IL-4Rs in protection from carcinogen-induced carcinogenesis. In 
addition, two studies have investigated the role of IL-4R signalling in 
Abbreviations: ACF, aberrant crypt focus; AI, apoptosis index; AOM, azoxy-
methane; BMI, body mass index; BrdU, 5-bromo-deoxyuridine; CAC, coli-
tis-associated CRC; CI, confidence interval; CRC, colorectal cancer; DKO, 
double-knockout; IL-4R, interleukin-4 receptor; IQR, interquartile range; 
MDSC, myeloid-derived suppressor cells; NSAID, non-steroidal anti-inflam-
matory drug; OR, odds ratio; SD, standard deviation; SNP, single nucleotide 
polymorphism; STAT-6, signal transducer and activator of transcription-6; 
WT, wild-type.
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mouse models of colitis-associated CRC (CAC) (11,18). Osawa et al. 
(18) reported that IL-4-null BALB/c mice developed fewer colorectal 
tumours (although these authors noted frequent ACFs) than wild-type 
(WT) animals when treated with AOM alone but noted no difference 
in tumour incidence between the two genotypes when AOM was used 
with trinitrobenzene sulphonic acid in order to model CAC. On the 
other hand, tumour multiplicity was reduced in IL-4Rα ‘knockout’ 
mice compared with WT animals in the AOM/dextran sulphate 
sodium model of CAC (11).
Given conflicting data on the effect of lack of IL-4Rα-mediated 
signalling and IL-4 gene deletion on AOM-induced colorectal car-
cinogenesis, we sought to investigate the effect of genetic deletion 
of IL-4Rα on tumour development and growth in the AOM model 
of ‘sporadic’ colorectal carcinogenesis. In addition, we used ‘double-
knockout’ (DKO) IL-4Rα−/− × IL-13−/− mice in order to investigate 
further the mechanisms underlying the pro-tumorigenic effect of lack 
of IL-4Rα-mediated signalling. 
Functional single nucleotide polymorphisms (SNPs) are recog-
nized in the human IL-4Rα gene with SNP rs1801275 being best 
characterized as a guanine for adenine substitution at nucleotide 
1902 (1902A>G), leading to a change from a glutamine to arginine 
residue at position 576 (Q576R) adjacent to a tyrosine phosphoryla-
tion site (Y575) in the cytoplasmic domain of IL-4Rα-chain (19,20). 
Early studies suggested that Q576R was associated with reduced 
SHP-1 phosphotyrosine phosphatase binding to the IL-4Rα chain 
and presumed loss of phosphatase activity against substrates includ-
ing STAT-6 (19). However, subsequent studies in human and mouse 
leucocytes did not find evidence of increased STAT-6 phosphoryla-
tion or downstream DNA binding (20,21). Moreover, the Q576R 
substitution and the IL-4Rα SNP rs1805015 (S503P) have also 
been associated with reduced phosphorylation of STAT-6, as well as 
increased phosphorylation of insulin receptor-like substrate (IRS) 1 
and 2 in human peripheral blood mononuclear cells consistent with 
Q576R as a ‘loss of function’ SNP (22). Importantly, similar studies 
have not yet been performed in non-haematopoietic cells expressing 
the type II IL-4R. Therefore, in parallel with our mechanistic mouse 
studies, we tested the hypothesis that ‘functional’ IL-4Rα SNPs, 
including the putative ‘loss of function’ SNP Q576R, are associated 
with increased CRC risk in a case–control human epidemiological 
study.
Methods
Animal studies
About 6- to 8-week-old male and female BALB/c animals from our existing 
colony of WT and IL-4Rα−/− mice were used (17). BALB/c mice harbouring a 
homozygous deletion of the IL-13 gene (IL-13−/−) were a kind gift from Prof. 
Andrew McKenzie, University of Cambridge (23). DKO IL-4Rα−/− × IL-13−/− 
mice were bred and genotyped by PCR (see Supplementary Methods, available 
at Carcinogenesis Online).
Animals received either two intraperitoneal injections of 10 mg/kg AOM 
(Sigma) or saline (sham) 1 week apart followed by killing 6 weeks later (ACF 
protocol), or received weekly 10 mg/kg AOM injections or sham saline injec-
tions for 6 weeks, for analysis 32 weeks later (tumour protocol).
Tissue/blood collection and analysis
In the tumour protocol, mice were administered 250 μl of 5-bromo-deoxyu-
ridine (BrdU; ~0.75 mg/kg BrdU, Cell Proliferation Labelling Reagent; GE 
Healthcare, Little Chalfont, UK) intraperitoneally 2 h before killing. All ani-
mals were killed by CO2 asphyxiation. Whole blood was obtained immediately 
after death by cardiac puncture.
Blood collection and haemocytometer analysis are described in 
Supplementary Methods, available at Carcinogenesis Online.
The whole colon was removed and flushed with phosphate-buffered saline. 
For the ACF protocol, the colon was opened, cleaned and fixed in 4% (wt/vol) 
paraformaldehyde in phosphate-buffered saline as described (17). For the 
tumour protocol at 32 weeks, the colon was first opened longitudinally onto a 
glass plate for examination of macroscopic tumours using an Olympus SZ60 
stereo-microscope fitted with a graticule (Southend, UK). The presence, posi-
tion and maximum diameter of each tumour were noted before excision for 
fixation in 4% paraformaldehyde overnight. The remaining colon was fixed 
separately in 4% paraformaldehyde for ACF counting. Fixed tissue was 
washed and stored in 70% (vol/vol) ethanol before embedding in paraffin.
The number and size (number of crypts per ACF) of ACFs were measured in 
methylene blue-stained fixed colon as described (17).
Splenocytes were obtained by mashing the whole spleen through a 70 μm 
mesh filter for immediate storage at −80°C in 90% (vol/vol) fetal calf serum 
and 10% (vol/vol) dimethylsulphoxide.
Flow cytometry and cytokine analysis
One million splenocytes were incubated with antibodies or an isotype control 
for 30 min at 4°C. Cells were analysed on a BD LSRII fluorescence-activated 
cell sorting analyser using fluorescence-activated cell sorting Diva software. 
Cytokine levels were measured by multiplex immunoassay. For more informa-
tion on flow cytometry and cytokine analysis, see Supplementary Methods, 
available at Carcinogenesis Online).
Immunohistochemistry
See Supplementary Methods, available at Carcinogenesis Online.
Statistical analysis
GraphPad Prism 5.02 software (GraphPad Software, San Diego, CA) was used 
to analyse the data from the experimental studies. P ≤ 0.05 was considered to 
be statistically significant.
The case–control epidemiology study
Patients with CRC were recruited between 1992 and 2011 from NHS hos-
pitals in Leeds and Harrogate as reported previously (24,25). Patients were 
invited to participate after a confirmed diagnosis of adenocarcinoma of the 
colorectum. Only cases that were recruited within 2  years of the date of 
CRC diagnosis were included. Cases were observed until death or the cen-
sor date of 20 June 2011. In the all-cause mortality survival analysis, death 
from any cause was the end point, whereas in the CRC-specific survival 
analysis, death from CRC was the end point and death from other causes 
was censored. Healthy, population-based, age-matched controls with no his-
tory of cancer were recruited via the same General Practice surgery or cases 
(spouses or friends) (24,25).
Six SNPs in the coding region of the human IL-4Rα gene [rs1801275 
(Q576R), rs1805015 (S503P), rs1805010 (I75V), rs1805011 (A400E), 
rs1805013 (S436L) and rs1805016 (A752S)] were genotyped using Taqman-
based allelic discrimination analysis. About 6% of DNA samples were ran-
domly duplicated across the different well plates for validation.
Detailed methodology is described in Supplementary Methods, available at 
Carcinogenesis Online. The distribution of age at diagnosis, sex, body mass 
index (BMI) at interview, smoking status (ever/never), taking vigorous physi-
cal activity and continuous non-steroidal anti-inflammatory drug (NSAID) 
use were compared between cases and controls. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated. The genotype distribution for each 
SNP was tested in controls for deviation from Hardy–Weinberg equilibrium. 
Genotype frequencies were compared between cases and controls using 
Pearson’s chi square test. ORs and 95% CIs were calculated from uncondi-
tional logistic regression, first unadjusted and then adjusted for sex and NSAID 
use, treating homozygosity for the common reference allele as the baseline 
risk category. For each SNP, crude hazard ratios and 95% CIs were estimated 
from Cox proportional hazards models for both CRC-specific mortality and 
all-cause mortality (see Supplementary Methods, available at Carcinogenesis 
Online, for more detail).
For a polymorphism with a risk genotype frequency of 12% in the control 
population, this study had >80% power to detect an OR of ≥1.5 at a signifi-
cance level of 0.05. The epidemiological data were analysed using Intercooled 
STATA version 9.0 (StataCorp LP, College Station, TX).
Results
Lack of IL-4Rα-mediated signalling is associated with increased 
AOM-induced ACF multiplicity but does not drive colorectal tumour 
development or growth
First, in an independent experiment using the ACF protocol, we 
confirmed our previous finding (17) that the number of colorectal 
ACFs that developed 6 weeks after AOM administration in BALB/c 
IL-4Rα−/− mice [median 8.5 ACFs per mouse (interquartile range, IQR 
5.75–12), n = 8] was significantly higher than the ACF multiplicity 
in WT controls [median 3 ACFs per mouse (IQR 1–3.5), n = 9; P 
= 0.007; Figure 1A]. However, lack of IL-4Rα-mediated signalling 
was not associated with ACF development in the absence of AOM 
treatment (Figure 1A).
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We also examined a cohort of mice, which had received a prolonged 
course of AOM, at 32 weeks as per the tumour protocol. At this time 
point, IL-4Rα −/− mice had a median of 8 ACFs per mouse (IQR 6–10; 
n = 16) compared with a median value of 3 ACFs per mouse (IQR 
2–7; n = 19) in WT animals (P = 0.002; Figure 1B). The size of ACFs, 
measured as the number of abnormal crypts per ACF, did not differ 
significantly between the two genotypes at either 6 or 32 weeks after 
AOM administration (Figure 1C and D). There was no difference in 
ACF multiplicity or size between male and female IL-4Rα −/− mice at 
either 6 weeks [median 9 (IQR 6.5–12.5) ACFs per female IL-4Rα −/−  
mouse (n = 5) compared with male animals with a median 8 (IQR 
0–12) ACFs (n = 3)] or 32 weeks [median 7.5 (IQR 5.75–14) ACFs 
per female IL-4Rα −/− mouse (n = 10) compared with male animals 
median 8 (IQR 6–9.25) ACFs (n = 6)].
No tumours were found in sham-treated animals at 32 weeks. 
Tumours in AOM-treated mice were restricted to females and were 
localized exclusively to the distal colon. All tumours were classified 
as carcinoma-in situ or high-grade dysplastic adenoma by a con-
sultant histopathologist (Figure 2A). In contrast with the effect of 
IL-4Rα deletion on ACF multiplicity, lack of IL-4Rα-mediated sig-
nalling did not promote macroscopic tumour development in female 
mice. At least 1 tumour was present in 5 of 14 (26.3%) of WT mice 
(mean 2 tumours per tumour-bearing mouse) compared with 4 of 
16 (25%) of IL-4Rα−/− mice (mean 1.4 tumours per tumour-bearing 
animal). However, tumours in IL-4Rα−/− mice were significantly 
smaller than tumours from WT mice [mean (standard deviation, 
SD) maximum tumour diameter 2.3 (1.0) mm in IL-4Rα−/− mice 
versus 3.7 (1.3) mm in WT mice; P = 0.05; Mann–Whitney U-test; 
Figure 2B].
There was no significant difference in BrdU positivity of epithelial 
cells in IL-4Rα−/− versus WT mice in either non-neoplastic mucosa 
or in adenomas (Figure 3A and B) suggesting that differences in epi-
thelial cell proliferation did not explain the differences observed in 
ACF formation (a biomarker of tumour initiation) or tumour growth. 
Counter-intuitively, we also observed a significantly lower apop-
tosis index (AI) in IL-4Rα−/− tumours compared with WT tumours 
(P  =  0.05; Mann–Whitney U-test; Figure  3C). However, smaller 
IL-4Rα−/− tumours contained a higher percentage of cells, which were 
negative for β-catenin immunoreactivity, or exhibited membranous 
staining only compared with WT animals (P = 0.04, Student’s t-test; 
Figure 3D and Supplementary Figure 1, available at Carcinogenesis 
Online).
Fig. 1. Lack of IL-4Ra-mediated signalling is associated with an increase in AOM-induced ACF multiplicity. (A) The number of ACFs per colon 6 weeks after 
sham or AOM treatment in WT and IL-4Rα−/− mice. Data are from individual mice. Bars represent the median value for each group. The number of mice within 
each group is noted below the treatment group labels. *P = 0.007; Mann–Whitney U-test. (B) The number of ACFs per colon 32 weeks after sham or AOM 
treatment in WT and IL-4Rα−/− mice. Data are from individual mice. Bars represent the median value for each group. The number of mice within each group 
is noted below the treatment group labels. *P = 0.002; Mann–Whitney U-test. (C) ACF size (measured as the number of abnormal crypts per ACF) in WT and 
IL-4Rα−/− mice 6 weeks after AOM administration. (D) ACF size in WT and IL-4Rα−/− mice 32 weeks after AOM administration. ACF size was not significantly 
different between WT and IL-4Rα−/− mice at either 6 or 32 weeks after AOM administration (both P = 0.7; Mann–Whitney U-test).
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Mechanisms driving intestinal tumorigenesis in the absence of 
IL-4Rα-mediated signalling
In our previous study of AOM-induced intestinal tumorigenesis using 
a short-term ACF protocol, we demonstrated that AOM administra-
tion was associated with a dramatic increase in serum tumour necrosis 
factor α level 6 weeks post-AOM injection and that genetic deletion 
of the IL-4Rα chain was associated with raised serum IL-4 levels 
(16). When we repeated this analysis at 32 weeks using the tumour 
AOM protocol, we observed that there was now no difference in the 
serum levels of the T helper 1 and 2 cytokines between the two mouse 
genotypes and that the tumour necrosis factor α response to AOM 
administration had disappeared, suggesting that both were short-
term, reversible phenomena (Supplementary Figure  2, available at 
Carcinogenesis Online). There was also no difference between serum 
cytokine levels of IL-1β, IL-6, IL-10 and IL-15 between the treatment 
groups and mouse genotypes (data not shown).
At 32 weeks, there was no significant difference in the number of 
circulating blood monocytes, granulocytes or lymphocytes between 
WT and IL-4Rα−/− mice (Supplementary Figure  3A, available at 
Carcinogenesis Online). We also examined splenic T lymphocyte 
(CD4+, CD8+ and CD25+ FoxP3+) populations, as well as the num-
ber of CD11b+ Gr1+ MDSCs (Supplementary Figure 3B, available at 
Carcinogenesis Online). We observed that splenic MDSC induction in 
AOM-induced tumour-bearing animals was absent in IL-4Rα−/− mice 
(Supplementary Figure 3B, available at Carcinogenesis Online).
We previously speculated that IL-13Rα2-mediated signalling by 
IL-13 might account for increased AOM-induced tumour initiation 
in IL-4Rα−/− mice based on increased colorectal mucosal expression 
of transforming growth factor β, upregulation of which is recognized 
to occur downstream of IL-13–IL-13Rα2 activation (17). In order to 
directly test the hypothesis that IL-4Rα-independent signalling by 
IL-13 contributes to increased initiation of chemical colon carcino-
genesis, we compared AOM-induced ACF multiplicity at 6 weeks in 
IL-13-null mice, as well as IL-13−/− × IL-4Rα−/− DKO animals, with 
IL-4Rα−/− and WT mice. Sham-treated IL-13−/− mice had a total of 
two unicryptal ACFs in five mice (data not shown). IL-13−/− animals 
developed a similar number and size of AOM-induced colorectal 
ACFs to IL4Rα−/− mice, both in excess of WT animals (Figure 4A and 
B). Lack of IL-13 did not abrogate the effect of absence of IL-4Rα-
mediated signalling in DKO animals, thereby refuting the hypothesis 
that increased tumour initiation in IL-4Rα−/− mice is dependent on 
IL-13 signalling. Instead, this evidence implicates a protective role 
for the type II IL-4R, for which both IL-4 and IL-13 are ligands, and 
which is the predominant IL-4R expressed by intestinal epithelial 
cells (11).
Functional IL-4Rα SNPs are associated with an increased risk of 
CRC but no difference in CRC survival
As the experimental studies demonstrated that genetic deletion of 
IL-4Rα is associated with increased tumour initiation, but not accel-
erated tumour growth, we tested whether altered IL-4Rα-mediated 
signalling would be associated with increased CRC risk, but a dif-
ferential effect on CRC outcomes after diagnosis, in a case–control 
epidemiological study.
We studied 1502 CRC cases and 584 controls, representing >80% 
of all eligible study participants (Table I) (24,25). About 99% of 
the total population was white British in origin, with 0.6% Afro-
Carribean, 0.6% Asian and 0.1% mixed race. As expected, there 
was a significantly smaller proportion of females in the CRC cases 
compared with controls (P ≤ 0.001) and significantly fewer CRC 
cases were continuous NSAID users compared with controls (P = 
0.008; Table I). Therefore, the logistic regression models to assess 
the effect of the SNPs on CRC susceptibility were adjusted for sex 
and NSAID use. A higher proportion of cases than controls had ever 
smoked, though the difference did not quite reach statistical sig-
nificance (P = 0.06). There were no differences in the distributions 
of age at diagnosis, BMI at interview or physical activity between 
cases and controls.
All genotype frequency distributions in the control group were in 
accordance with Hardy–Weinberg equilibrium. Haplotype analysis 
indicated that SNPs rs1805011, rs1805013, rs1805015, rs1805016 
and rs1801275 were all in strong linkage disequilibrium (data not 
shown). The associations between individual SNPs and CRC suscep-
tibility are shown in Table II. The strongest association with CRC 
susceptibility was observed for SNP rs1801275 (Q576R). Increased 
risk of CRC was observed in homozygotes of the rare allele (GG) 
compared with common reference allele homozygotes (AA) with a 
Ptrend of 0.04 (Table II). In the adjusted analysis, the OR was 1.54 
(95% CI 0.94–2.54; P = 0.089) for the homozygous G allele. Ptrend for 
the association between the G allele and CRC risk was 0.03. There 
were no statistically significant differences in CRC risk in the overall 
population for the other SNPs investigated (Table II).
When stratified by sex, genotype effects on increased CRC 
susceptibility were stronger than those observed in the overall 
analysis, with significant increased risks seen only in females for 
Fig. 2. AOM-induced tumour characteristics in BALB/c mice. (A) All 
tumours exhibited high-grade dysplasia. There was no invasion of the 
muscularis mucosa, so tumours were classified as carcinoma in situ. Size 
bar = 100 μm. (B) The size (maximum diameter) of colonic tumours in WT 
and IL-4Rα−/− mice. Data points represent individual adenomas and the bars 
indicate the median value for each group. *P = 0.05 (Mann–Whitney U-test) 
for the difference between genotypes.
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SNPs rs1801275 (Q576R), rs1805015 (S503P) and rs1805011 
(A400E; Supplementary Table I, available at Carcinogenesis 
Online). Further assessment of gender and IL-4Rα genotypes in 
the control population indicated that an increased frequency of 
the common homozygote for the SNPs in females was driving this 
statistical interaction. No significant differences were found in an 
analysis of gender and genotype by a case-only Pearson’s chi square 
test [rs1801275 df(1) P = 0.31; rs1805015 df(1) P = 0.29; rs1805011 
df(1) P = 0.56].
Stratification by site of CRC (colon versus rectum) was also carried 
out (data not shown). There was a statistically significant relationship 
between SNP rs1801275 (Q576R) and colon cancer risk, but not for 
rectal cancer. Carriage of at least one G allele conferred an OR for 
colon cancer of 1.27 (95% CI 1.02–1.58, P = 0.03, adjusted for sex 
and NSAID use) when compared with common AA homozygotes. 
The corresponding adjusted OR for rectal cancer was 1.09 (95% CI 
0.84–1.42, P = 0.50).
For the survival analysis, some cases from the susceptibility study 
were excluded due to missing data or blood being drawn >2 years after 
CRC diagnosis. Therefore, 1145 cases were included in the survival 
analysis. There was a mean follow-up duration of 61.1 months (range 
5.0–237.6 months). The 5 year survival from CRC-related death for 
all patients was 64.8%. As expected, survival differed according to 
Dukes’ stage at the time of diagnosis (Supplementary Table 2, avail-
able at Carcinogenesis Online; P < 0.001).
Supplementary Table 2, available at Carcinogenesis Online, shows 
the unadjusted hazard ratios and 95% CIs for the relationship between 
the IL-4Rα SNPs and CRC-specific mortality, as well as all-cause 
mortality. As expected, age (P < 0.001) and sex (P = 0.016) affected 
all-cause mortality. Histological differentiation and pathological stage 
of the primary CRC affected CRC-specific mortality (Ptrend < 0.001), 
with a stronger effect on CRC survival. None of the six IL-4Rα SNPs 
showed significant effects on CRC or overall survival in unadjusted 
analyses or in analyses adjusting for age, sex, ever smoked, patho-
logical stage and histological differentiation (data not shown). No 
significant relationship between the IL-4Rα SNPs and mortality were 
observed when the data were stratified by sex or tumour site (data not 
shown).
Discussion
We have defined stage-specific effects of reduced IL-4Rα-mediated 
signalling on colorectal carcinogenesis in an established rodent model 
of chemical ‘sporadic’ colorectal carcinogenesis and confirmed the 
relevance of the pre-clinical observations in a case–control human 
epidemiological study of IL-4Rα SNPs.
We observed a clear distinction between increased tumour initiation 
(increased ACF multiplicity) and no effect on progression to adenoma 
and reduced tumour growth (demonstrated by no difference in AOM-
induced tumour incidence and reduced tumour size) in IL-4Rα-null 
Fig. 3. Biomarkers of proliferation, apoptosis and tumour growth at 32 weeks after AOM administration. (A) The BrdU crypt proliferation index in non-neoplastic 
mucosa from WT and IL-4Rα−/− mice. For each genotype, data are the mean and standard error of a minimum of 149 crypts counted in 8 separate mice. P = 0.25 
for the difference between WT and IL-4Rα−/− animals (Mann–Whitney U-test). (B) The BrdU proliferation index in WT (n = 6) and IL-4Rα−/− (n = 6) tumours. 
Individual tumour proliferation index values are shown with bars representing the mean value. A mean of 1296 (SD = 514) dysplastic epithelial cells per adenoma 
was counted. P = 0.12 for the difference between WT and IL-4Rα−/− animals (Mann–Whitney U-test). (C) Cleaved caspase 3 AI in WT (n = 6) and IL-4Rα−/− 
(n = 5) tumours. Individual tumour AI values are shown with bars representing the mean value. A mean of 2643 (SD = 582) dysplastic epithelial cells per adenoma 
was counted (*P = 0.05; Mann–Whitney U-test). (D) β-Catenin localization in dysplastic cells in AOM-induced colonic tumours from WT and IL-4Rα−/− mice. 
A mean of 860 cells per adenoma was assessed for β-catenin localization by immunohistochemistry. The results are presented as the mean of the percentage of 
cells with no or membranous β-catenin staining and nuclear and/or cytoplasmic β-catenin staining per adenoma from WT (n = 6) and IL-4Rα−/− mice (n = 6).
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mice compared with WT animals. The association of rs1801275 
(Q576R), a SNP affecting downstream IL-4Rα-mediated signalling 
linked to possible reduction in STAT-6 phosphorylation (22), with 
increased colonic cancer risk, but not CRC-related mortality, in 
females in our epidemiological study concurs with the stage-specific 
effects of IL-4Rα deletion demonstrated in the pre-clinical model. 
Therefore, IL-4Rα, like transforming growth factor β and forkhead 
box O3 for example (26,27), is a gene that appears to play different 
roles at different stages during colorectal carcinogenesis.
These data argue that pharmacological inhibition of IL-4Rα signal-
ling, currently being developed for treatment of asthma and inflamma-
tory bowel disease (28,29), could have deleterious consequences for 
future ‘sporadic’ CRC risk and any therapy involving IL-4R antago-
nism requires careful long-term evaluation in order to monitor colo-
rectal adenoma and CRC risk. On the other hand, our pre-clinical data 
demonstrating smaller tumour size on an IL-4Rα−/− background hint 
that IL-4Rα antagonism could have a therapeutic role in treatment of 
established CRC. It would be very interesting to investigate the effect 
of treatment with the IL-4 mutein pitrakinra (28) on human CRC cell 
tumour xenograft growth in nude mice, in the first instance.
An interesting observation arising from our use of two different 
AOM administration protocols is that the number and size of ACFs 
did not change over time. It remains unclear whether ACFs are true 
precursor lesions, a small proportion of which can lead directly to 
macroscopic tumour formation, or whether ACFs are solely a surro-
gate mucosal biomarker of mucosal instability that predicts de novo 
tumour development elsewhere in the colon. Shpitz et al. (30) have 
provided indirect evidence that a small number of ACFs probably are 
true precursor lesions, but that the majority of ACFs are stable over 
time. Stable ACF multiplicity and size over time after AOM adminis-
tration in our study are compatible with the concept that the ACF is, 
in fact, a biomarker of tumour growth. We are not aware of any previ-
ous literature comparing ACF multiplicity in early and late phases 
after AOM administration. However, the ACF number we report is 
consistent with existing literature on AOM-induced carcinogenesis in 
BALB/c mice (31).
Fig. 4. Lack of IL-13-mediated signalling does not abrogate the increase in AOM-mediated ACF development in IL-4Rα−/− mice compared with WT animals. 
(A) The number of ACFs per colon 6 weeks after sham or AOM treatment in WT, IL-13−/−, IL-4Rα−/− and IL-4Rα−/− × IL-13−/− DKO mice. Data are from 
individual mice. Bars represent the median value for each group. The number of mice within each group is noted below the treatment group labels. (B) ACF 
size (measured as the number of abnormal crypts in each ACF) in WT, IL-13−/−, IL-4Rα−/− and DKO mice 6 weeks after AOM administration. There was no 
significant difference between the genotypes (Kruskal–Wallis test followed by Dunn’s multiple comparison test). 
2346
IL-4 receptor signalling and colorectal carcinogenesis
The mechanism(s) by which reduced IL-4Rα-mediated signalling 
leads to reduced tumour growth remains unclear. We ruled out a sim-
ple effect on the balance between tumour cell proliferation and apop-
tosis. In fact, counter-intuitively, smaller IL-4Rα ‘knockout’ tumours 
exhibited reduced numbers of apoptotic cells compared with WT ade-
nomas. The Fingleton laboratory has previously noted a difference in 
proliferation and apoptosis indices of IL-4Rα-null versus WT tumours 
depending on whether tumour growth occurred in a WT or IL-4Rα-
null host (11). Lack of tumour cell IL-4Rα signalling alone in a WT 
host resulted in reduced tumour cell proliferation but no change in AI 
(11). However, combined lack of host and tumour IL-4Rα signalling 
was associated with an increase in AI, as well as a reduction in pro-
liferation (11). The discrepancy between our data and those of Koller 
et al. (11) may be related to the use of dextran sulphate sodium in the 
latter study in order to model CAC rather than ‘sporadic’ colorectal 
carcinogenesis.
We did demonstrate that a lack of IL-4Rα-mediated signalling is 
associated with less nuclear and cytoplasmic β-catenin staining in epi-
thelial cells in colonic adenomas. Similar findings have been reported 
by Koller et al. (11). WNT/β-catenin pathway dysregulation is criti-
cal for tumour progression and growth (32) suggesting that there 
may be a causal link between reduced tumour growth and β-catenin 
Table II.  The relationship between IL-4Rα SNPs and CRC susceptibility
SNP Controls Cases Unadjusted Adjusteda
n (%)b n (%)b OR 95% CI P value OR 95% CI P value
rs1801275 AA 364 (63.1) 847 (58.5) 1.0 1.0
Q576R AG 190 (32.9) 524 (36.2) 1.19 (0.96–1.46) 0.107 1.18 (0.96–1.46) 0.121
GG 23 (4.0) 77 (5.3) 1.44 (0.89–2.33) 0.139 1.54 (0.94–2.54) 0.089
Trend 1.19 (1.01–1.41) 0.041 1.21 (1.02–1.43) 0.033
rs1805015 TT 400 (69.4) 951 (65.7) 1.0 1.0
S503P TC 158 (27.4) 442 (30.5) 1.18 (0.95–1.46) 0.140 1.16 (0.93–1.45) 0.186
CC 18 (3.1) 54 (3.7) 1.26 (0.73–2.18) 0.404 1.40 (0.79–2.47) 0.249
Trend 1.16 (0.97–1.38) 0.111 1.17 (0.97–1.40) 0.097
rs1805016c TT 525 (91.1) 1288 (89.0) 1.0 1.0
A752S TG 51 (8.9) 155 (10.7) 1.24 (0.89–1.73) 0.207 1.27 (0.90–1.79) 0.168
GG 0 (0.0) 4 (0.3) NA NA
Trend 1.29 (0.94–1.79) 0.120 1.34 (0.96–1.87) 0.086
rs1805013c CC 536 (92.3) 1308 (90.5) 1.0 1.0
S436L CT 44 (7.6) 136 (9.4) 1.27 (0.89–1.81) 0.191 1.34 (0.93–1.93) 0.116
TT 1 (0.2) 2 (0.1) 0.82 (0.07–9.06) 0.871 1.04 (0.09–11.82) 0.976
Trend 1.24 (0.88–1.74) 0.222 1.31 (0.92–1.87) 0.129
rs1805011 AA 439 (77.3) 1073 (76.0) 1.0 1.0
A400E AC 117 (20.6) 305 (21.6) 1.07 (0.84–1.36) 0.599 1.06 (0.83–1.36) 0.628
CC 12 (2.1) 33 (2.3) 1.13 (0.58–2.20) 0.730 1.14 (0.57–2.24) 0.714
Trend 1.06 (0.87–1.30) 0.544 1.06 (0.86–1.31) 0.558
rs1805010 AA 162 (28.8) 428 (30.4) 1.0 1.0
I75V AG 295 (52.4) 700 (49.7) 0.90 (0.72–1.13) 0.352 0.91 (0.72–1.15) 0.421
GG 106 (18.8) 280 (19.9) 1.00 (0.75–1.33) 0.999 0.99 (0.73–1.33) 0.928
Trend 0.99 (0.86–1.14) 0.871 0.98 (0.85–1.14) 0.826
aAdjusted for sex and NSAID use.
bThe total number of cases and controls differ across SNPs reflecting a small number of failed SNP assays.
cSNPs rs1805016 and rs1805013 are in strong linkage disequilibrium with a Dʹ value of 0.9.
Table I. Characteristics of CRC cases and controls in the IL-4Rα SNP study 
Characteristic Statistic Controls Cases Unadjusted OR (95% CI) P valuea
584b 1502b
Age (years) Mean (SD) 67.3 (9.3) 67.3 (10.5) 1.00 (0.99, 1.01) 0.96
Sex
 Male n (%) 273 (46.8) 881 (58.7) 1.0
 Female 311 (53.3) 621 (41.3) 0.62 (0.51, 0.75) <0.001
Ever smoked
 No n (%) 248 (42.7) 504 (38.2) 1.0
 Yes 333 (57.3) 816 (61.8) 1.21 (0.99, 1.47) 0.06
BMI (kg/m2) Mean (SD) 26.3 (4.5) 26.0 (4.3) 0.99 (0.96, 1.01) 0.19
Vigorous physical activityc
 No n (%) 415 (72.4) 920 (70.3) 1.0
 Yes 158 (27.6) 389 (29.7) 1.11 (0.89, 1.38) 0.35
NSAID (continuous use)d
 No n (%) 375 (64.5) 932 (70.7) 1.0
 Yes 206 (35.5) 386 (29.3) 0.75 (0.61, 0.93) 0.008
aSignificance values (P) were calculated by Pearson’s chi square for sex, ever smoked and vigorous physical activity. Student’s t-test was used for age and BMI 
comparisons.
bThe number of cases and controls analysed for each factor varied slightly because of missing data.
cVigorous physical exercise was defined by the question “In a typical week one year ago, did you exercise (includes housework, DIY, gardening, walking) 
vigorously enough to cause sweating or a faster heartbeat?”
dContinuous NSAID use was defined by the question “Have you ever taken NSAIDs on a regular basis for periods of 3 months or longer?”
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localization in IL-4Rα−/− tumours. Moreover, IL-4 drives catenin-
related transcription in mouse thymocytes via GATA-3 and SATB1 
transcription factors (33). Further work should now explore cross-talk 
between IL-4Rα- and catenin-related signalling in colorectal epithe-
lial cells with either ‘loss of function’ adenomatous polyposis coli 
mutations or ‘gain of function’ CTNNB1 (β-catenin) mutations.
Using a transgenic approach, we explored further the mechanism 
underlying the pro-tumorigenic effect of the lack of IL-4Rα signal-
ling. The fact that IL-13 deletion mirrored the effect of IL-4Rα dele-
tion on AOM-induced ACF formation and that IL-13 deletion did not 
abrogate the effect of lack of IL-4Rα-mediated signalling in DKO 
mice implicates a tumour suppressor role for the type II IL-4R (of 
which IL-4 and IL-13 are both ligands), rather than a tumour sup-
pressor role of the type I  IL-4R, or pro-tumorigenic activity of the 
IL-13Rα2 receptor. Several studies have previously reported localiza-
tion of IL-4Rα chain protein to epithelial cells in 60–90% of human 
CRCs and in mouse CRC (11,34–36). Although upregulation of 
IL-4Rα chain protein expression in CRC compared with non-neoplas-
tic colorectal epithelial cells is a consistent finding, there are conflict-
ing data regarding whether IL-4Rα chain protein is actually expressed 
by non-neoplastic colorectal epithelial cells in humans (11,34–36).
We noted that IL-4Rα−/− mice failed to generate a CD11b+ Gr1+ 
MDSC response to colorectal tumours, consistent with the existing 
literature (16). Therefore, one hypothesis that requires testing is that 
reduced AOM-induced tumour growth, after the initiation phase, in 
IL-4Rα−/− mice is due to increased host antitumour immunocompetence 
resulting from an impaired IL-4Rα-dependent tumour-driven MDSC 
response. However, the small size of AOM-induced colorectal tumours 
did not allow us to investigate whether IL-4Rα−/− tumours contained 
less MDSCs and CD8+ lymphocytes by flow cytometry in keeping 
with this hypothesis. Recent reports describing the association of 
circulating and tumour-infiltrating MDSCs with CRC progression in 
clinical studies highlight the potential relevance of these cells to the 
functional consequences of reduced IL-4R function during colorectal 
carcinogenesis (37,38).
Our epidemiological findings that there is increased risk of CRC 
with each addition of the rs1801275 G allele contradict results pub-
lished by Lee et al. (39). In their Korean case–control study, Lee et al. 
(39) reported decreased CRC risk associated with the 1902T>C SNP 
(rs1801275) (39). However, their study sample size was significantly 
smaller than our study (170 cases and 130 controls) with a consequent 
high risk of false-positive associations. In a slightly larger study than 
that of Lee et al. (39) (377 cases and 326 controls), Landi et al. (40) 
demonstrated no association between the same IL-4Rα SNP and CRC 
risk. Within our study, we have 72% power to detect a minimal OR 
of 1.8 for a rare homozygote of 4% frequency in the control popula-
tion. Further work now needs to be conducted on independent data 
sets to confirm the association between IL-4Rα SNPs and CRC risk 
and survival.
Previous studies in haematopoietic cells have failed to conclude the 
functional consequences of the Q576R substitution on downstream 
signal transduction (19–22). However, the rs1801275 SNP has been 
associated with other pathologies including end-stage renal disease 
(41) and glioma (42) suggesting that Q576R may have functional con-
sequences in non-haematopoietic cells. In the future, it will be essen-
tial to determine the effects of IL-4Rα SNPs including Q576R on 
human intestinal epithelial cell biology and kinase/phosphotyrosine 
phosphatase signal transduction. Interestingly, increased insulin 
receptor-like substrate 1 phosphorylation, which is a downstream con-
sequence of the Q576R substitution in peripheral blood mononuclear 
cells (21), has recently been implicated in CRC progression (43).
Conclusion
In summary, we provide pre-clinical evidence, backed up by human 
epidemiological observations, which together suggest that reduced 
type II IL-4R signalling is associated with increased ‘sporadic’ CRC 
risk, but no strong effect on CRC progression or clinical outcomes. 
These data should drive studies of the effect of pharmacological 
manipulation of type II IL-4R signalling in animal models of different 
stages of colorectal carcinogenesis with a view to determining the risk/
benefit balance of targeting the IL-4R in different patient populations 
at risk of, or with established, CRC.
Supplementary material
Supplementary Methods, Tables 1 and 2 and Figures 1–3 can be found 
at http://carcin.oxfordjournals.org/
Funding
Yorkshire Cancer Research (L332) and Cancer Research UK (C588/
A10589 and C37059/A11941). Engineering and Physical Sciences 
Research Council (EP/I000623/1 to N.I.). Medical Research Council 
(UK) Senior Clinical Fellowship (to M.A.H.).
Conflict of Interest Statement: None declared.
References
 1. Chan,A.T. et  al. (2010) Primary prevention of colorectal cancer. 
Gastroenterology, 138, 2029–2043.e10.
 2. Lasisi,F. et al. (2011) Improving protection against proximal colon cancer 
by colonoscopy. Expert Rev. Gastroenterol. Hepatol., 5, 745–754.
 3. Zauber,A.G. et al. (2012) Colonoscopic polypectomy and long-term pre-
vention of colorectal-cancer deaths. N. Engl. J. Med., 366, 687–696.
 4. Wu,X. et al. (2011) Chemoprevention–history and general principles. Best 
Pract. Res. Clin. Gastroenterol., 25, 445–459.
 5. Terzić,J. et al. (2010) Inflammation and colon cancer. Gastroenterology, 
138, 2101–2114.e5.
 6. Ben-Nariah,Y. et  al. (2011) Inflammation meets cancer, with 
NFκnflammation meets ca Nature Immunol., 12, 715–723.
 7. Nelms,K. et al. (1998) Interleukin-4 receptor signalling mechanisms and 
their biological significance. Adv. Exp. Med. Biol., 452, 37–43.
 8. Terabe,M. et al. (2004) Role of IL-13 in regulation of anti-tumor immunity 
and tumor growth. Cancer Immunol. Immunother., 53, 79–85.
 9. Fichtner-Feigl,S. et  al. (2006) IL-13 signaling through the IL-13alpha2 
receptor is involved in induction of TGF-beta1 production and fibrosis. 
Nat. Med., 12, 99–106.
 10. Kawakami,K. et al. (2001) Overexpressed cell surface interleukin-4 recep-
tor molecules can be successfully targeted for antitumor cytotoxin therapy. 
Crit. Rev. Immunol., 21, 299–310.
 11. Koller,F.L. et al. (2010) Epithelial interleukin-4 receptor expression pro-
motes colon tumor growth. Carcinogenesis, 31, 1010–1017.
 12. Terabe,M. et al. (2000) NKT cell-mediated repression of tumor immuno-
surveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol., 1, 
515–520.
 13. Olver,S. et al. (2007) The duplicitous effects of interleukin 4 on tumour 
immunity: how can the same cytokine improve or impair control of tumour 
growth? Tissue Antigens, 69, 293–298.
 14. Li,Z. et  al. (2008) Endogenous interleukin-4 promotes tumor develop-
ment by increasing tumor cell resistance to apoptosis. Cancer Res., 68, 
8687–8694.
 15. Todaro,M. et  al. (2008) Apoptosis resistance in epithelial tumors is 
mediated by tumor-cell-derived interleukin-4. Cell Death Differ., 15, 
762–772.
 16. Gallina,G. et  al. (2006) Tumors induce a subset of inflammatory mono-
cytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest., 
116, 2777–2790.
 17. Ko,C.W. et al. (2008) Lack of interleukin-4 receptor alpha chain-dependent 
signalling promotes azoxymethane-induced colorectal aberrant crypt focus 
formation in Balb/c mice. J. Pathol., 214, 603–609.
 18. Osawa,E. et  al. (2006) Predominant T helper type 2-inflammatory 
responses promote murine colon cancers. Int. J. Cancer, 118, 2232–2236.
 19. Hershey,G.K. et al. (1997) The association of atopy with a gain-of-func-
tion mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. 
J. Med., 337, 1720–1725.
 20. Wang,H.Y. et  al. (1999) Cutting edge: effects of an allergy-associated 
mutation in the human IL-4R alpha (Q576R) on human IL-4-induced 
signal transduction. J. Immunol., 162, 4385–4389.
 21. Tachdjian,R. et  al. (2009) Pathogenicity of a disease-associated 
human IL-4 receptor allele in experimental asthma. J. Exp. Med., 206, 
2191–2204.
2348
IL-4 receptor signalling and colorectal carcinogenesis
 22. Kruse,S. et al. (1999) The polymorphisms S503P and Q576R in the inter-
leukin-4 receptor alpha gene are associated with atopy and influence the 
signal transduction. Immunology, 96, 365–371.
 23. McKenzie,G.J. et al. (1998) A distinct role for interleukin-13 in Th2-cell-
mediated immune responses. Curr. Biol., 8, 339–342.
 24. Barrett,J.H. et  al. (2003) Investigation of interaction between 
N-acetyltransferase 2 and heterocyclic amines as potential risk factors for 
colorectal cancer. Carcinogenesis, 24, 275–282.
 25. Lightfoot,T.J. et al. (2008) Methylene tetrahydrofolate reductase genotype 
modifies the chemopreventive effect of folate in colorectal adenoma, but 
not colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 17, 2421–2430.
 26. Lampropoulos,P. et al. (2012) TGF-beta signalling in colon carcinogenesis. 
Cancer Lett., 314, 1–7.
 27. Tenbaum,S.P. et al. (2012) β-catenin confers resistance to PI3K and AKT 
inhibitors and subverts FOXO3a to promote metastasis in colon cancer. 
Nat. Med., 18, 892–901.
 28. Burmeister Getz,E. et  al. (2009) Human pharmacokinetics/pharmacody-
namics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J. 
Clin. Pharmacol., 49, 1025–1036.
 29. Kopf,M. et  al. (2010) Averting inflammation by targeting the cytokine 
environment. Nat. Rev. Drug Discov., 9, 703–718.
 30. Shpitz,B. et al. (1996) Natural history of aberrant crypt foci. A  surgical 
approach. Dis. Colon Rectum, 39, 763–767.
 31. Hosono,K. et  al. (2010) Metformin suppresses azoxymethane-induced 
colorectal aberrant crypt foci by activating AMP-activated protein kinase. 
Mol. Carcinog., 49, 662–671.
 32. Schmalhofer,O. et al. (2009) E-cadherin, beta-catenin, and ZEB1 in malig-
nant progression of cancer. Cancer Metastasis Rev., 28, 151–166.
 33. Notani,D. et al. (2010) Global regulator SATB1 recruits beta-catenin and 
regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol., 8, 
e1000296.
 34. Kaklamanis,L. et  al. (1992) Interleukin-4 receptor and epidermal 
growth factor receptor expression in colorectal cancer. Br. J. Cancer, 66, 
712–716.
 35. Todaro,M. et  al. (2007) Colon cancer stem cells dictate tumor growth 
and resist cell death by production of interleukin-4. Cell Stem Cell, 1, 
389–402.
 36. Formentini,A. et  al. (2012) Expression of interleukin-4 and interleu-
kin-13 and their receptors in colorectal cancer. Int. J. Colorectal Dis., 27, 
1369–1376.
 37. Sun,H.L. et  al. (2012) Increased frequency and clinical significance of 
myeloid-derived suppressor cells in human colorectal carcinoma. World 
J. Gastroenterol., 18, 3303–3309.
 38. Zhang,B. et al. (2013) Circulating and tumor-infiltrating myeloid-derived 
suppressor cells in patients with colorectal carcinoma. PLoS ONE, 
8:e57114.
 39. Lee,Y.S. et  al. (2010) Association between interleukin-4R and TGF-β1 
gene polymorphisms and the risk of colorectal cancer in a Korean popula-
tion. Colorectal Dis., 12, 1208–1212.
 40. Landi,S. et  al. (2007) Interleukin-4 and interleukin-4 receptor polymor-
phisms and colorectal cancer risk. Eur. J. Cancer, 43, 762–768.
 41. Jimenez-Sousa,M.A. et al. (2012) Genetic polymorphisms located in genes 
related to immune and inflammatory processes are associated with end-
stage renal disease: a preliminary study. BMC Med. Genet., 13, 58.
 42. Li,S. et  al. (2012) Polymorphisms of TREH, IL4R and CCDC26 genes 
associated with risk of glioma. Cancer Epidemiol., 36, 283–287.
 43. Esposito,D.L. et  al. (2012) The insulin receptor substrate 1 (IRS1) in 
intestinal epithelial differentiation and in colorectal cancer. PLoS One, 7, 
e36190.
Received March 15, 2013; revised June 10, 2013; accepted June 11, 2013
2349
